Clinical trials: Population Medicine
Drug Drug Interaction
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
The drug-drug interaction study has been designed to investigate the effect of Fluvoxamine, Itraconazole and Paroxetine on the pharmacokinetics of ASN51
- Trial name
- NCT06232109
- Testing
- Fluvoxamine, Itraconazole, Paroxetine
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Asceneuron S.A.
Neuromuscular Agents, Peripheral Nervous System Agents
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence.
- Conditions
- Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
- Trial name
- PLATINUM US (NCT07122193)
- Testing
- NT 201
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Merz North America, Inc.
Obesity, Hepatic Insufficiency
Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
CP-945,598 is eliminated following extensive metabolism. Decrease hepatic function can affect its elimination from the body via metabolism.
- Trial name
- NCT00645021
- Testing
- CP-945,598
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tuberculosis
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
This study measured the early bactericidal activity (EBA), safety, tolerability and pharmacokinetics of GSK3036656 in combination with either delamanid, bedaquiline or BTZ-043 and delamanid in combination with bedaquiline or…
- Trial name
- NCT05382312
- Testing
- GSK3036656, Bedaquiline, Delamanid
- Where
- South Africa
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Duodenal Ulcer
Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer
The purpose of this study is to determine the efficacy of TAK-438, once daily (QD), compared to lansoprazole in patients with duodenal ulcer.
- Trial name
- NCT01452724
- Testing
- TAK-438, Lansoprazole
- Where
- 64 sites in Japan
- Volunteers
- 372 people
- Sponsor
- Takeda
Healthy
A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function
This study is being done to learn more about an investigational medicine called PF-08653944. The goal is to understand how the body handles the medicine and to check its safety after a single dose.
- Trial name
- NCT07519135
- Testing
- PF-08653944
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Efficacy and Safety In Poorly Controlled Type 2 Diabetics
The purpose of this study is to gain safety and efficacy information in patients with type 2 diabetes, who have not previously taken any oral antidiabetic medications, and who have an HbA1c value of greater than or equal to 10%…
- Trial name
- NCT00044460
- Testing
- rosiglitazone
- Volunteers
- 142 people
- Sponsor
- GlaxoSmithKline
Spasticity, Multiple Sclerosis
A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.
The purpose of this study is to evaluate the efficacy, safety and tolerability of Sativex® in subjects diagnosed with MS and spasticity.
- Trial name
- NCT00711646
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 189 people
- Sponsor
- Jazz Pharmaceuticals
Acne Vulgaris
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
To demonstrate the efficacy, therapeutic equivalence and safety of Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and US Reference Listed Drug, Canadian Reference Product over the placebo control in the treatment of…
- Trial name
- NCT06733402
- Testing
- Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Venous Thromboembolism
Dose-confirmatory Bridging Study in Total Hip Replacement
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing…
- Trial name
- NCT01205932
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 41 sites in Japan
- Volunteers
- 402 people
- Sponsor
- Bayer
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Austria Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01667016
- Where
- 8 sites in Austria
- Volunteers
- 305 people
- Sponsor
- Biotronik Vertriebs-GmbH
Diabetes, Diabetes Mellitus, Type 2
Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to compare BIAsp 30 twice daily individually adjusted by the subject versus BIAsp 30 twice daily individually adjusted by the investigator both combined with oral…
- Trial name
- NCT01618214
- Testing
- biphasic insulin aspart 30
- Where
- 22 sites in China
- Volunteers
- 344 people
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers
A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants
The purpose of this study is to compare the PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.
- Trial name
- NCT03948581
- Testing
- Vedolizumab SC
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Takeda
Migraine, Medication Overuse Headache
Eptinezumab in Adults With Migraine and Medication Overuse Headache
This study evaluates the efficacy of eptinezumab to prevent migraine and headache in patients with the combined diagnosis of migraine and medication overuse headache
- Trial name
- Sunlight (NCT04772742)
- Testing
- Eptinezumab
- Where
- 40 sites in China, Georgia and 3 more
- Volunteers
- 193 people
- Sponsor
- H. Lundbeck A/S
Hypertension
An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of TCV-116CCB (candesartan cilexetil and amlodipine besylate fixed-dose combination) in Chinese participants with mild to moderate hypertension who do not reach…
- Trial name
- NCT02969265
- Testing
- Amlodipine, TCV-116CCB
- Where
- 25 sites in China
- Sponsor
- Takeda
Multiple Sclerosis
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone…
- Trial name
- CONFIDENCE (NCT02499900)
- Testing
- Copaxone®
- Where
- 97 sites in United States, Argentina and 14 more
- Volunteers
- 861 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Hepatitis C, Chronic
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
To evaluate the drug-drug interactions between BI 201335 and BI 207127 as well as their combined effect on CYP probe drug substrates and on tenofovir and raltegravir in treatment naive or prior treatment relapse patients with…
- Trial name
- NCT01525628
- Testing
- midazolam, BI 201335, tenofovir
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
Dyslipidemia
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia
The purpose of this study is to evaluate the overall safety of Lapaquistat Acetate, once daily (QD), by itself or in combination with atorvastatin in subjects with primary dyslipidemia.
- Trial name
- NCT00487994
- Testing
- Lapaquistat acetate, Lapaquistat acetate and atorvastatin, Atorvastatin
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 2,130 people
- Sponsor
- Takeda
Migraine, Medication Overuse Headache
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins).
- Trial name
- RESOLUTION (NCT05452239)
- Testing
- Eptinezumab
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 608 people
- Sponsor
- H. Lundbeck A/S
Bioequivalence, Phase 1
A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects
This study aims to demonstrate pharmacokinetic (PK) similarity of biosimilar candidate CinnoRA® relative to adalimumab reference product (Humira®) and evaluate safety and tolerability of CinnoRA®, in a parallel fashion in healthy…
- Trial name
- NCT03273192
- Testing
- Adalimumab
- Where
- Iran
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Cinnagen